Inhibition of nitric oxide formation by guanidines
- PMID: 7506664
- DOI: 10.1016/0014-2999(93)90667-7
Inhibition of nitric oxide formation by guanidines
Abstract
Aminoguanidine, N,N'-diaminoguanidine, methylguanidine, and 1,1-dimethylguanidine were compared to NG-monomethyl-L-arginine (L-NMMA) for their ability to inhibit nitric oxide (NO) formation by cytokine-inducible and vascular constitutive isoforms of NO synthase. These comparisons were performed by assessing (1) cytokine-induced production of nitrite by RINm5F cells, (2) vasoconstrictor responses of isolated rat mesenteric arteries, and (3) in vivo blood pressure responses following intravenous bolus injection into anesthetized rats. Aminoguanidine and L-NMMA were the most potent inhibitors of cytokine-induced NO formation in RINm5F cells, while the other guanidine compounds were 10 (1,1-dimethylguanidine) to 100 (methylguanidine) times less potent. L-NMMA and 1,1-dimethylguanidine were the most potent inhibitors of the vascular constitutive isoform of NO synthase in both assay systems, while aminoguanidine and N,N'-diaminoguanidine were the least potent. These results (1) confirm the selective inhibition of the inducible isoform of NO synthase by aminoguanidine, (2) indicate that N,N'-diaminoguanidine, while approximately 30 times less potent than aminoguanidine in inhibiting inducible NO synthase, has very little effect on constitutive NO synthase activity, and (3) 1,1-dimethylguanidine, like L-NMMA, is a relatively potent inhibitor of both isoforms of NO synthase.
Similar articles
-
Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation.Diabetes. 1993 Feb;42(2):221-32. doi: 10.2337/diab.42.2.221. Diabetes. 1993. PMID: 7678825
-
Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction.Diabetes. 1992 Apr;41(4):552-6. doi: 10.2337/diab.41.4.552. Diabetes. 1992. PMID: 1376704
-
Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo.Eur J Pharmacol. 1995 Jan 16;272(2-3):169-75. doi: 10.1016/0014-2999(94)00637-m. Eur J Pharmacol. 1995. PMID: 7536162
-
Effects of guanidino and uremic compounds on nitric oxide pathways.Kidney Int. 1994 Mar;45(3):737-42. doi: 10.1038/ki.1994.98. Kidney Int. 1994. PMID: 7515129
-
Aminoguanidine selectively inhibits inducible nitric oxide synthase.Br J Pharmacol. 1993 Nov;110(3):963-8. doi: 10.1111/j.1476-5381.1993.tb13907.x. Br J Pharmacol. 1993. PMID: 7507781 Free PMC article.
Cited by
-
Human and rat macrophages mediate fungistatic activity against Rhizopus species differently: in vitro and ex vivo studies.Infect Immun. 1995 Nov;63(11):4489-94. doi: 10.1128/iai.63.11.4489-4494.1995. Infect Immun. 1995. PMID: 7591090 Free PMC article.
-
Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase.Br J Pharmacol. 1996 May;118(2):261-70. doi: 10.1111/j.1476-5381.1996.tb15397.x. Br J Pharmacol. 1996. PMID: 8735625 Free PMC article.
-
Selective inhibition of human inducible nitric oxide synthase by S-alkyl-L-isothiocitrulline-containing dipeptides.Br J Pharmacol. 2001 Apr;132(8):1876-82. doi: 10.1038/sj.bjp.0704023. Br J Pharmacol. 2001. PMID: 11309260 Free PMC article.
-
Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity.Br J Pharmacol. 1995 Jan;114(2):510-6. doi: 10.1111/j.1476-5381.1995.tb13256.x. Br J Pharmacol. 1995. PMID: 7533622 Free PMC article.
-
Beneficial effects of aminoguanidine on skin flap survival in diabetic rats.Exp Diabetes Res. 2012;2012:721256. doi: 10.1155/2012/721256. Epub 2012 Dec 13. Exp Diabetes Res. 2012. PMID: 23304118 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources